(Q33347028)

26 July 2017

title

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507 (English)

1 reference

26 July 2017

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

1 reference

1 reference

I Sekine

1

1 reference

26 July 2017

Y Nishiwaki

2

1 reference

26 July 2017

R Kakinuma

3

1 reference

26 July 2017

K Kubota

4

1 reference

26 July 2017

F Hojo

5

1 reference

26 July 2017

T Matsumoto

6

1 reference

26 July 2017

H Ohmatsu

7

1 reference

26 July 2017

K Goto

8

1 reference

26 July 2017

T Kodama

9

1 reference

26 July 2017

K Eguchi

10

1 reference

26 July 2017

T Shinkai

11

1 reference

26 July 2017

T Tamura

12

1 reference

26 July 2017

Y Ohe

13

1 reference

26 July 2017

H Kunitoh

14

1 reference

26 July 2017

K Yoshimura

15

1 reference

26 July 2017

N Saijo

16

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

88

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

808-813

1 reference

The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC).

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377075

Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377075

Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377075

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377075

Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377075

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377075

Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377075

The calculation of actual or received dose intensity: a comparison of published methods.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377075

Brief Intensive Chemotherapy for Metastatic Non-Small-Cell Lung Cancer: A Phase II Study of the Weekly CODE Regimen

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377075

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600800

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

21 January 2018

1 reference

12 December 2020

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

12 December 2020

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

12 December 2020

Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study

1 reference

12 December 2020

Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer

1 reference

12 December 2020

Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600800

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference